These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37407731)

  • 21. Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
    van der Veen L; Segers M; van Raay JJ; Gerritsma-Bleeker CL; Brouwer RW; Veeger NJ; van Hulst M
    BMJ Open; 2021 Jan; 11(1):e040336. PubMed ID: 33462096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
    Bohula EA; Berg DD; Lopes MS; Connors JM; Babar I; Barnett CF; Chaudhry SP; Chopra A; Ginete W; Ieong MH; Katz JN; Kim EY; Kuder JF; Mazza E; McLean D; Mosier JM; Moskowitz A; Murphy SA; O'Donoghue ML; Park JG; Prasad R; Ruff CT; Shahrour MN; Sinha SS; Wiviott SD; Van Diepen S; Zainea M; Baird-Zars V; Sabatine MS; Morrow DA;
    Circulation; 2022 Nov; 146(18):1344-1356. PubMed ID: 36036760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy.
    Kumar D; Kaimaparambil V; Chandralekha S; Lalchandani J
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
    INSPIRATION-S Investigators
    BMJ; 2022 Jan; 376():e068407. PubMed ID: 34996756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eligibility for Posthospitalization Venous Thromboembolism Prophylaxis in Hospitalized Patients With COVID-19: A Retrospective Cohort Study.
    Vaughn VM; Ratz D; McLaughlin ES; Horowitz JK; Flanders SA; Middleton EA; Grant PJ; Kaatz S; Barnes GD
    J Am Heart Assoc; 2022 Oct; 11(19):e025914. PubMed ID: 36073649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
    Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Sharifova G; Cohen M; Lund JM; Mignatti A; Gianos E; Tafur A; Lewis PA; Cohoon K; Kittelson JM; Lesser ML; Sison CP; Rahman H; Ochani K; Hiatt WR; Dale RA; Anderson VE; Bonaca M; Halperin JL; Weitz JI; Spyropoulos AC
    Thromb Haemost; 2021 Dec; 121(12):1684-1695. PubMed ID: 33823560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Lins PRG; de Albuquerque CCC; Assis CF; Rodrigues BCD; E Siqueira Campos BP; de Oliveira Valle E; Cabrera CPS; de Oliveira Gois J; Segura GC; Strufaldi FL; Mainardes LC; Ribeiro RG; Via Reque Cortes DDP; Lutf LG; de Oliveira MFA; Sales GTM; Smolentzov I; Reichert BV; Andrade L; Seabra VF; Rodrigues CE
    Trials; 2020 Nov; 21(1):920. PubMed ID: 33176886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
    J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial :
    Longo de Oliveira ALM; de Oliveira Pereira RF; Agati LB; Ribeiro CM; Kawamura Suguiura GY; Cioni CH; Bermudez M; Pirani MB; Caffaro RA; Castelli V; Resende Aguiar VC; Volpiani GG; Paschoa A; Scarlatelli Macedo AV; de Barros E Silva PGM; de Campos Guerra JC; Fareed J; Lopes RD; Ramacciotti E
    Clin Appl Thromb Hemost; 2022; 28():10760296221132556. PubMed ID: 36474344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
    Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P;
    Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
    Field TS; Dizonno V; Almekhlafi MA; Bala F; Alhabli I; Wong H; Norena M; Villaluna MK; King-Azote P; Ratnaweera N; Mancini S; Van Gaal SC; Wilson LK; Graham BR; Sposato LA; Blacquiere D; Dewar BM; Boulos MI; Buck BH; Odier C; Perera KS; Pikula A; Tkach A; Medvedev G; Canfield C; Mortenson WB; Nadeau JO; Alshimemeri S; Benavente OR; Demchuk AM; Dowlatshahi D; Lanthier S; Lee AYY; Mandzia J; Suryanarayan D; Weitz JI; Hill MD;
    Stroke; 2023 Nov; 54(11):2724-2736. PubMed ID: 37675613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
    O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG;
    Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.
    Ena J; Valls V
    Clin Exp Med; 2023 Aug; 23(4):1189-1196. PubMed ID: 36048371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.